ABSTRACT-Regulation of ornithine decarboxylase (ODC) expression at a promotion stage of lung carcinogenesis is a key clue to suppress the cancer. In this study, we investigated that the ODC induction at the promotion stage of lung carcinogenesis in mice could be inhibited through the suppression of the expression of c-myc, a transcription factor for ODC. The treatment with c-myc antisense oligonucleotide decreased the carcinogen-elevated level of pulmonary ODC protein at the promotion stage, but the sense oligonucleotide had no influence on the level. Overall, it is possible that the induction of ODC in the carcinogenic process of lung is regulated at its transcriptional level.
Ornithine decarboxylase (ODC), the first and key enzyme in polyamine biosynthesis, is essential for cell proliferation and is induced by growth stimuli (1, 2) . The ODC gene is now recognized as an early response gene required for progression into the S-phase of the cell cycle and as a proto-oncogene (3, 4). The regulation of ODC in normal tissue is rigid, but the regulation in human cancer becomes uncontrollable based on its mutation (5), leading to the stimulation of polyamine biosynthesis and subsequent abnormal cell proliferation. Thus, correcting the abnormality of polyamine biosynthesis during carinogenesis may contribute to the preventive effect of the carcinogenesis. In fact, DL-a -difluoromethylornithine, which is an irreversible inhibitor of ODC, has been reported to inhibit chemical carcinogensis in many tissues (6).
We have already reported that the suppression of pulmonary ODC induction contributes to the reduction of the development of lung tumors in mice (7). Recently, we found that this suppressive effect was partly based on the regulation of the expression of the ODC gene at its transcriptional level, mainly through the modulation of transcription activity of c-myc (8). It means that the transcriptional regulation of c-myc-dependent ODC induction in the carcinogenic process of the lung is an important clue to reduce the development of lung tumors. In this context, this study was undertaken to estimate if the down-regulation of ODC in lung carcinogenesis could be through the suppression of c-myc, a main transcription factor for ODC transcription, by using its antisense oligonucleotide. Here we show that the inhibition of c-myc expression by its antisense oligonucleotide treatment is linked with the downregulation of ODC transcription.
Specific pathogen-free A/J strain female mice (SLC, Shizuoka) were used in this study. All mice had ad libitum access to AIN-76A diet and sterilized water. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the most potent carcinogen among tabacco-specific nitrosamines, was purchased from Chemysyn Science Laboratories (Lenexa, KS, USA), and this carcinogen dissolved in saline was once administered to mice intraperioneally at a dose of 100 mg/ kg body weight on the first day of experiment.
The c-myc antisense and sense (phosphorothioate) oligonucleotides were obtained from Pharmacia Biotech (Tokyo) upon our request. The sequence of the sense oligonucleotide was 5'-ATGCCCCTCAACGTGAACTTC-3' and that of the antisese was 5'-GAAGTTCACGTTGAGGGGCAT-3' (9). They were designed to overlap the initiation codon of *Corresponding author. FAX: +81-3-3205-6549 E-mail: yano@nih.go.jp the c-myc mRNA. Oligonucleotide was dissolved in phosphate-buffered saline (50 mg/ ml). To prepare the oligonucleotide-liposome complex, we used a cationic liposome DMRIE-C as a vehicle in accordance with the recommendation of the supplier (Life Technologies, Rockville, MD, USA), and the complex was prepared immediately prior to injection. After incubation for adequate time at room temperature, the oligonucleotide-liposome solution (0.2 ml /mouse) was subcutaneously injected into mice as a dose of 0.25 mg/kg body weight on day 30 after NNK injection. The control group was treated with vehicle only. Sense oligonucleotide was used as a negative control. At 24 h after the injection, all mice were sacrificed to assay the level of ODC and c-myc proteins. This treatment condition was optimized according to our previous report (8) and preliminary study. Soluble fractions were prepared from 10% lung homogenates in lysis buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM aprotinin, 20 mM leupeptin and 5 mM sodium vanadate, by centrifugation at 4°C for 30 min at 10,000´g. The supernatant was used to determine the level of ODC protein. Nuclear extracts were prepared according to an established method (10), and these extracts were used for the determination of the level of c-myc protein. The solubilized samples were boiled for 3 min, separated on 10% SDS-polyacrylamide gel electrophoresis and electrophoretically blotted on nitrocellulose filters. Immunoblot analyses were performed by using anti-ODC antibody (Sigma, St. Louis, MO, USA) and anti-c-myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The blots were developed with the ECL system (Amersham, Arlington Heights, IL, USA). The relative amounts of ODC and c-myc proteins were calculated by densitometric analysis.
We have shown that a chemopreventive agent-related suppression of ODC gene expression at the promotion stage of lung tumorigenesis is partly based on the control of its transcriptional level (8). At present, it is known that four transcription factors (AP-1, c-myc, cAMP-responseelement-binding proteins and Sp1) can modulate ODC gene transcription (11 -14). Of these factors, we have indicated that c-myc can act as only the transcription factor for the ODC gene expression in lung tumorigenesis (8). In this context, we tried to estimate if the suppression of function of c-myc as the transcription factor was linked with the down-regulation of ODC. In order to reduce the c-myc function, we used c-myc antisense oligonucleotide and suppressed c-myc level. As shown in Fig. 1 , compared to the level of ODC protein in the control, the level in NNKtreated group increased. Similarily, the level of c-myc protein was elevated by NNK treatment. The treatment with c-myc antisense oligonucleotide drastically decreased the NNK-elevated level of c-myc protein, and in parallel, the amount of ODC protein reduced (Fig. 2: a and b) . Also, c-myc sense treatment did not influence the level of c-myc and ODC proteins (Fig. 2: a and b) . Furthermore, the antisense oligonucleotide treatment did not affect the amount of both the proteins in the control (data not shown). In addition to our previous report (8), the present results further support the notion that the induction of ODC in the carcinogenic process of lung is regulated at its transcriptional level.
ODC is subject to a complex array of cell-specific regulatory mechanisms that govern transcription, mRNA stability and translation, and enzyme degradation (15). Normally, ODC is degraded rapidly in cells, and its halflife is less than 1 h (5). However, the half-life of ODC in human tumor cells is prolonged due to its resistance to enzyme degradation, and the stabilization of ODC is a critical reason why ODC activity is higher in tumor cells than in normal cells and contributes to less differentiation of tumor cells (5). In such cells overproducing ODC, inhibitors against ODC such as DL-= -difluoromethylornithine can not usefully suppress the tumor growth in vitro (15). On the contrary, even if the tumor cells are resistant to inhibitors against ODC, an agent targeting ODC gene transcription can reduce the overproduction of ODC in vitro (14). Thus, if this beneficial effect in vitro can be applied to an in vivo system, it seems to establish a useful prevention and therapy for cancer based on the regulation of ODC transcription. In this study, we clearly demonstrated that the in vivo control of ODC transcription reduced the elevated level of ODC protein in the carcinogenic process of the lung. Furthermore, we have reported that a vitamin E derivative suppresses the induction of ODC at its transcriptional level and subsequent cell proliferation in a mouse lung carcinogenesis model (8). Overall, to develop agents able to regulate ODC transcription may lead to the establishment of a promising prevention and therapy for lung cancer.
